Dr. Bram Bout joins Bioceros as CEO

Utrecht, The Netherlands, July 2, 2007: Bioceros B.V., a privately held biopharmaceutical research and development contract organization, announced today that Dr. Bram Bout will join the company from July 1st, 2007 as Chief Executive Officer. Remco Brandt, Managing director of Bioceros commented: “I am excited that Mr. Bout is willing to take over the position of CEO. With his expertise and network Bioceros can offer now a full pre-clinical package to customers, including molecular biology, serum-free cell line generation, production at 20L scale and product testing. This also allows Bioceros to develop it’s own product portfolio. In connection with the above mentioned, the management board of Bioceros B.V. has been restructured reflecting the new corporate structure and identity. The new executive board will comprise out of Dr. Bout as CEO, Mr. Brandt as Chief Operating Officer and Dr. Boon as Chief Scientific Officer.

Prof. dr. Mark de Boer, Chairman of the Supervisory board, added: “With Mr. Bout joining the team a major step has been taken towards a more balanced company. On one hand the CRO activities will generate revenues and on the other hand the company will create its own platform & portfolio.”

-ENDS-

Notes for editors

About Bram Bout
Prior to joining Bioceros, Bram Bout was Vice President, Protein Production, Crucell Holland BV, The Netherlands, a biotech company to develop, produce and market vaccines worldwide to combat infectious and other diseases and to leverage its proprietary technologies to develop monoclonal antibodies and therapeutic protein products. Bram was co-inventor of the PER.C6© production platform which offer an attractive production technology for the development and manufacturing of a wide range of biopharmaceuticals such as: Vaccines, Antibodies, Therapeutic Proteins and Gene Therapy Products.

About Bioceros B.V.
Bioceros is headquartered in Utrecht, the Netherlands and founded in 2003. The company is a contract research organization with a focus on collaborative research with other biotechnology companies, pharmaceutical enterprises and academic institutions in the field of immunology, specifically auto-immune diseases, oncology and infectious diseases. In addition the Company provides cell line generation and pilot production services at pre-clinical scale.

For more information: Bioceros B.V.:
Remco M. Brandt, M.Sc.
Managing director
tel. +31 30 253 7910
info@bioceros.com
www.bioceros.com

Publisher Contact Information:

Bioceros
+31 30 253 7910
info@bioceros.com

Company profile of Bioceros (acquired by Epirus)
Past press releases of Bioceros (acquired by Epirus).